Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:002294)

Market Cap	41.59B -22.8%
Revenue (ttm)	4.52B +13.4%
Net Income	676.45M +12.4%
EPS	0.60 +11.2%
Shares Out	1.11B
PE Ratio	62.14
Forward PE	n/a
Dividend	0.55 (1.48%)
Ex-Dividend Date	May 26, 2026

Volume	38,464,905
Open	36.30
Previous Close	37.26
Day's Range	35.88 - 40.00
52-Week Range	29.25 - 70.99
Beta	-0.16
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About SHE:002294

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceuticals and medical devices in China. The company is involved in the production and supply of pharmaceutical products in the fields of chronic diseases, including cardiovascular and cerebrovascular diseases, diabetes, oncology, osteoporosis, anti-infective diseases, and chronic kidney diseases. It also engages in the research and development, production, and sale of high-end interventional medical devices, such as cardiovascular and...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 4,087
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002294

Financial Performance

In 2025, SHE:002294's revenue was 4.35 billion, an increase of 8.48% compared to the previous year's 4.01 billion. Earnings were 651.50 million, an increase of 8.30%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 20, 2026

Data Sources Report a data error